Sana Biotechnology upgraded at Citizens on valuation

 

• Sana Biotechnology (NASDAQ:SANA) was upgraded to Market Outperform from Market Perform at Citizens as the research broker believes the company's stock is undervalued.
• SANA is down 20% in morning trade.
• "With three-month follow-up from the modified pancreatic islet cell IST program validating the HIP platform in T1D, SC291 data in autoimmune diseases (AID) expected in 2025, and a cash position of $152.5MM, we believe Sana shares are undervalued, given the stock has retraced some of its gains after the initial T1D data release," Citizens' analysts said.
• Citizens has a price target of $5 for the company.
• SANA stock has fallen 75% in the last twelve months.

https://www.msn.com/en-us/money/markets/sana-biotechnology-upgraded-at-citizens-on-valuation/ar-AA1Bakio